• In late June 2026, AnaptysBio, Inc. was removed from the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth benchmark indices, while also entering a one-year sublease agreement to rent out its San Diego facility to First Tracks Biotherapeutics.
• This combination of index deletions and the move to sublease a significant amount of office space highlights shifting index representation alongside efforts to optimize AnaptysBio’s real estate commitments.
• With AnaptysBio’s removal from multiple Russell indices and a new sublease in place, we’ll explore how these developments influence its investment narrative.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

What Is AnaptysBio's Investment Narrative?

To own AnaptysBio today, you have to believe its royalty and immunology pipeline story outweighs current volatility and losses, and that the planned separation into a lean royalty vehicle plus a development-focused biopharma can create value over time. The recent removal from multiple Russell indices may add short-term trading pressure as passive funds exit, but the share price has already moved sharply over the past year, suggesting this shift in index representation may not be the dominant driver of sentiment right now. The San Diego sublease looks more like housekeeping: it helps trim real estate costs as AnaptysBio transitions to a lower FTE model, without altering the key near-term catalysts around clinical readouts, the GSK collaboration dispute, or execution on the spin-off plan. The biggest risks remain execution missteps, litigation outcomes and funding against ongoing losses.

However, investors should be aware of how litigation and index exclusion could affect liquidity and sentiment. AnaptysBio's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span roughly US$87 to US$349 per share, underlining just how far apart views can be. Set against the recent index removals and ongoing restructuring, this spread shows why you may want to weigh several different perspectives before deciding how AnaptysBio’s risks and catalysts fit your own expectations.

Explore 2 other fair value estimates on AnaptysBio - why the stock might be worth over 5x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your AnaptysBio research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free AnaptysBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AnaptysBio's overall financial health at a glance.

Seeking Other Investments?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.